OVER THE LAST FEW years, significant advances were made in the treatment of patients with chronic lymphocytic leukemia (CLL). Several novel therapies, most of them oral, have now been approved by the Food and Drug Administration. These include Imbruvica (ibrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor; Venclexta (venetoclax), a B-cell lymphoma-2 (BCL2) inhibitor; and Zydelig (idelalisib), a phosphoinositide 3-kinase (PI3K) inhibitor.
Venclexta (venetoclax), a BCL-2 inhibitor, had promising results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). According to an updated analysis of a clinical trial, the agent led to negative minimal residual disease (MRD) in 40 percent of patients involved.
Researchers are identifying targets to treat chronic lymphocytic leukemia.
Imbruvica (ibrutinib) continues to demonstrate benefit in patients with chronic lymphocytic leukemia (CLL) who had at least one prior therapy, according to a four-year follow-up of the RESONATE study, which compared the BTK inhibitor to Arzerra (ofatumumab).
As Ed completes his final chemo cycle, he loses a friend.
Having multiple options for frontline treatment of CLL may be better than deciding on one standard, an expert says.
The treatment landscape for chronic lymphocytic leukemia (CLL) is going to drastically change over the next decade or so, says Jose Leis, M.D.
Novel therapeutic agents have been developed for chronic lymphocytic leukemia (CLL), but their advantage over traditional treatments for this type of cancer have yet to be proved.
There are now more personalized treatment options for patients with CLL.
Arzerra was approved in combination with fludarabine and cyclophosphamide to treat patients with CLL.
As new therapies get approved and continue to be investigated, treatment for CLL is rapidly evolving.
The FDA expanded the label for Imbruvica for some patients with CLL, as the drug continues to show improved survival benefits.
The FDA approved Venclexta for patients with CLL who have a 17p deletion and failed at least one prior therapy.
The treatment landscape of chronic lymphocytic leukemia is rapidly evolving, according to Jeffrey Jones, an assistant professor at The Ohio State University Comprehensive Cancer Center.
The landscape for treating CLL is changing, bringing about questions and hope for a cure.
Patients taking novel treatments for CLL, and their caregivers, should know which side effects to expect — and recognize when they become emergencies.
In the phase 3 RESONATE-2 study, Imbruvica improved progression-free survival (PFS) by 84 percent in previously untreated patients with CLL or SLL.
The approval was based on a near doubling in progression-free survival (PFS) seen with the treatment compared with observation in the phase 3 PROLONG trial.
Ed chronicles part II of his chronic lymphocytic leukemia (CLL) story from the third person.
In an interview with CURE, John C. Byrd discusses the efficacy of acalabrutinib and how it compares with Imbruvica.
Less than two years after Imbruvica gained approval for patients with CLL, a second-generation agent has demonstrated a 95 percent response rate.
The results showed a two-year overall survival rate of 98 percent with Imbruvica.
CURE spoke with Wierda at the 2015 Chemotherapy Foundation Symposium, a meeting of over 1,000 oncologists and oncology professionals.
Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor (CAR) T-cell therapy.
A phase 3 study exploring Zydelig in combination with Treanda and Rituxan for patients with previously treated CLL has been stopped early following a positive interim analysis.
